On September 15, 2026, Insilico Medicine announced a research concept called "Longevity Vaccines." The target isn't a pathogen. The approach uses lipid nanoparticles to deliver circular RNA (a circularized form of messenger RNA) into T-cells in the body, temporarily instructing them to produce receptors that identify senescent and other aging-related cells. The company states it uses AI to select these cell-surface markers, with immune aging as its initial focus.
However, this is not the result of a candidate drug trial—it is an announcement of a research initiative. The company has not disclosed its specific target antigens, CAR structure, lipid composition, animal data, or clinical trial plans. While prior mouse studies exist for each individual technology, and a closely related therapeutic modality has already entered Phase 1 human trials, what's new here is the assembly of these elements into a single blueprint aimed at preventing aging.
The Announcement Describes In Vivo CAR-T, Not a Traditional "Vaccine"
Conventional infectious disease vaccines present antigens to the immune system to build immunological memory in preparation for a pathogen. Insilico's proposed mechanism is different. Targeted lipid nanoparticles deliver circular RNA into T-cells, which then use that RNA to express a Chimeric Antigen Receptor (CAR). The result is T-cells that recognize and attack specific cell-surface antigens.
This approach is known as in vivo CAR-T (a method of expressing chimeric antigen receptors on T-cells directly within the body). Unlike conventional CAR-T therapy—where T-cells are extracted from a patient, genetically modified in a facility, and then reintroduced—this method completes the cell engineering process inside the body. Because circular RNA lacks free ends, it is more resistant to degradation than linear RNA, but it is not designed for permanent integration into the genome. The company cites the eventual cessation of expression as the basis for its "self-limiting" safety design.
However, "transient" does not necessarily mean "a single dose provides long-term prevention." Even if CAR expression disappears within days, the effect might persist if the target cells are sufficiently eliminated. Conversely, if elimination is incomplete, re-administration may be necessary. Without measuring the duration of expression, the depth of cell clearance, and the immune response to repeat dosing, it remains unclear whether these two conditions can coexist.
Three Technologies Have Converged, But No Drug Candidate Exists Yet
The three technological pillars supporting the "Longevity Vaccine" concept have each been validated in separate studies, but as a unique combination specific to Insilico, neither the target antigens nor the animal data have been made public. Organizing the publicly available primary sources by what was actually tested yields the following:
| Year / Source | What Was Verified | Subject and Stage Reached | Boundary with Current Announcement |
|---|---|---|---|
| 2020: Nature | Senescent cell-clearing CAR-T targeting uPAR | Mouse models of lung cancer, liver fibrosis, etc. | Persistent CAR-T generated ex vivo |
| 2022: Science | Delivery of CAR-encoding modified mRNA to T-cells via targeted LNPs | Mouse model of cardiac fibrosis | Used linear RNA; targeted FAP on activated fibroblasts |
| 2025: Cell Reports Medicine | In vivo expression of uPAR CAR using circular RNA and PL40 LNPs | Mouse models of liver fibrosis and arthritis | Closest prior precedent, but not conducted by Insilico |
| 2026: NCT07413341 | Phase 1 trial of circular RNA/LNP in vivo CAR-T | Refractory autoimmune disease; planned for 12 patients; results not yet published | Targets CD19; not aimed at aging prevention |
| 2026: Insilico Announcement | Longevity vaccine concept using AI-selected targets | Announcement of research initiation | Candidate antigens and animal/human data undisclosed |
This table does not represent a timeline of a single drug candidate progressing smoothly through clinical development. Each study was conducted by a different research entity. The targeted molecules, lipid nanoparticle designs, and disease models are not identical across studies. What it demonstrates is that the necessary components have begun moving forward independently in different locations—and that the work of reassembling them into a preventive immune rejuvenation therapy remains unfinished.
The Rationale for Targeting Senescent Cells Was Built Up in Mice
The concept of using CAR-T to eliminate senescent cells traces back to a 2020 Nature paper. Corina Amor and colleagues compared multiple models of cellular senescence and selected the urokinase-type plasminogen activator receptor (uPAR) as a candidate. CAR-T cells targeting uPAR reduced uPAR-positive senescent cells both in vitro and in mice, improving survival in a drug-induced senescent lung adenocarcinoma model and tissue markers in a chemically and dietarily induced liver fibrosis model.
A 2023 Nature Aging paper expanded the scope to age-related metabolic decline. The research team preconditioned mice aged 18-20 months with 200mg/kg of cyclophosphamide and administered 500,000 anti-uPAR CAR-T cells. In aged mice and mice on a high-fat diet, markers of glucose metabolism and physical performance improved, and the report noted no clear toxicity in the pathology of examined tissues or in liver/kidney function.
In experiments involving preventive administration to young mice, the CAR-T cells persisted and proliferated for over 15 months, with effects observed well into old age. However, this longevity is a characteristic of persistent CAR-T cells generated ex vivo. This figure cannot be directly applied to the current concept, which uses circular RNA to temporarily generate CARs. Furthermore, improvements in glucose metabolism and running tests do not equate to lifespan extension or systemic rejuvenation in humans.
Senescent cells themselves are not a monolithic entity. Cells that have ceased proliferating due to DNA damage or other factors release inflammatory molecules through the Senescence-Associated Secretory Phenotype (SASP), which can damage tissue if allowed to persist. On the other hand, cellular senescence also plays a role in suppressing tumorigenesis and promoting wound healing. Therefore, what is required is not a technology that eliminates all senescent cells, but an antigen that can distinguish only the pathological ones.
Measuring the Distance to Humans from Prior Circular RNA Research
The principle of generating transient CAR-T cells within the body was substantiated by a 2022 Science paper. The research team encapsulated modified mRNA encoding a CAR that recognizes Fibroblast Activation Protein (FAP) into LNPs targeting CD5 on the T-cell surface. In vitro, 83% of mouse T-cells were CAR-positive after 48 hours, compared to 7% with non-targeted LNPs. In mice with cardiac injury, 17.5% to 24.7% of splenic T-cells were CAR-positive after 48 hours, but this was undetectable after one week.
Even closer to the current announcement is a 2025 paper in Cell Reports Medicine. Zihan Zhang and colleagues developed a PL40 lipid that delivers RNA preferentially to T-cells without requiring surface-attached antibodies, using it to express uPAR CAR via circular RNA. In mice with liver fibrosis induced by carbon tetrachloride over five weeks, four doses of 30µg were administered, with markers related to senescence and fibrosis examined in groups of six mice each. Markers for both liver fibrosis and collagen-induced arthritis improved, but the therapeutic experiments were confined to mice.
The modality as a whole has begun moving toward confirming safety in humans. NCT07413341, registered with ClinicalTrials.gov, is a Phase 1 trial delivering circular RNA encoding a CD19 CAR via T-cell-targeted LNPs, planned for 12 patients with refractory autoimmune disease. This open-label, dose-escalation trial began on January 22, 2026, and as of September 16, results have not yet been posted. It is neither a trial targeting senescent cells nor an Insilico product.
AI Can Rank Targets, But It Doesn't Prove Safety
Insilico uses its PandaOmics platform to analyze multi-layered omics data and literature, ranking cell-surface antigens based on expression timing and tissue specificity. The company's concept further involves using generative models to design binding molecules and ionizable lipids, while its Virtual Aging Cell platform aims to capture age-related changes in cellular states. The goal is to identify markers at the point when a cell begins to deviate from a healthy state, rather than molecules that appear after disease has already progressed.
A 2024 paper on PandaOmics evaluated 23 models across 12 therapeutic areas, measuring how effectively they could enrich known targets and disease-associated genes within the top 100 results. While this supports the validity of the candidate discovery process, it does not guarantee that the specific antigen in this case is absent from normal organs. This is because surface molecule expression changes with age and disease, and which cells an LNP enters is also influenced by the internal biological environment.
For a preventive therapy, the safety bar is high. Unlike treatments that weigh benefits against risks in sick patients, this could potentially be administered to asymptomatic individuals. Researchers need to examine, across all body tissues and over long observation periods, the risk of toxicity from attacking the same antigen on normal tissue, cytokine release, and the danger of depleting necessary immune cells. AI can narrow down the candidates. But the final verdict rests with experimentation.
Insilico's concept can be judged to have transitioned into a drug candidate once the target antigen and lymphocyte type are publicly disclosed, and animal studies demonstrate selective delivery to T-cells along with data on toxicity to normal tissue. Following that, data on the duration of CAR expression, the length of sustained efficacy, and the feasibility of re-administration will be required. Only once these pieces are in place, along with a candidate name and clinical trial registration, will the "Longevity Vaccine" advance from a research concept to a verifiable medicine.